Statement: the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments.
Primary_evidence: INTERVENTION 1:    Topical Saline   Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule   Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 2:    Topical Liquid Lidocaine   Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule   Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness
Secondary_evidence: INTERVENTION 1:    Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)   Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). INTERVENTION 2:    Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)   Participants received eribulin mesilate 1.6 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1).